Drug Topics December 9, 2024
Killian Meara, Ashley Gallagher, Kevin Cowart, PharmD, MPH, BCACP, FCCP, BCPS

A discussion with Kevin Cowart, PharmD, MPH, BCACP, FCCP, BCPS, assistant professor at the University of South Florida Taneja College of Pharmacy.

Since continuous glucose monitors (CGM) were first introduced in 1999, they have quickly become a mainstay of diabetes management. Research has shown that the devices can lead to reductions in glucose variability, HbA1c levels, average blood glucose levels, and hypoglycemic events, while also increasing a patient’s time spent within the target blood sugar range.1

However, CGMs remain underutilized. According to data published in the journal Clinical Diabetes, around 50% of commercially insured patients with type 1 diabetes do not use a CGM device despite the known benefits. The authors of the study identifying populations with lagging utilization is...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Conferences / Podcast, Digital Health, Patient / Consumer, Provider, Technology, Trends, Wearables
Related Articles:
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients
B2B Wearables: A New Tool for Businesses to Promote Workplace Wellness
Q&A: Continuous health monitoring with wearables
Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Tozo S6 Affordable Smartwatch Suits Almost Any Lifestyle

Share This Article